| CLINICAL PHARMACOLOGY |
|
| Year : 2020 | Volume
: 36
| Issue : 1 | Page : 104-109 |
|
|
Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention
Shuchita Garg1, Malti Vij2, Neeraj Edward1, Brinder Vij3
1 Department of Anesthesia and Pain Medicine, Division of Headache Medicine, University of Cincinnati, Cincinnati, Ohio, USA
2 Department of Internal Medicine, Division of Headache Medicine, University of Cincinnati, Cincinnati, Ohio, USA
3 Department of Neurology and Rehab Medicine, Division of Headache Medicine, University of Cincinnati, Cincinnati, Ohio, USA
Correspondence Address:
Dr. Shuchita Garg
Department of Anesthesia and Pain Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/joacp.JOACP_3_19
|
|
|
Headaches and migraines continue to be a leading cause of suffering and disability. As per the Global Burden of Disease Survey conducted in 2010, the exact magnitude of the disease still is underestimated. Migraine alone continues to rank seventh as a cause of disability. Various therapeutic modalities exist and newer classes of medications are currently being trialed to provide effective treatment to this population of patients. Erenumab, a calcitonin gene-related peptide receptor inhibitor, is a recent addition to this armamentarium and has been approved by the FDA for use in 2018. It has shown modestly improved outcomes according to the current trials. However, long-term outcomes and adverse effects still are under research. The following article elaborates on the current literature and evidence on this novel drug.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
